IDEXX Laboratories (IDXX) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

IDEXX Laboratories (IDXX) posted its quarterly earnings results on Friday. The company reported $0.72 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.71 by $0.01. The company’s quarterly revenue was up 10.2% on a year-over-year basis.

A number of research firms have also recently commented on IDXX. Analysts at Feltl & Co. raised their price target on shares of IDEXX Laboratories from $87.50 to $90.00 in a research note to investors on Monday, April 23rd. They now have a “hold” rating on the stock. On the ratings front, analysts at Leerink Swann upgraded shares of IDEXX Laboratories from a “market perform” rating to an “outperform” rating in a research note to investors on Monday, April 23rd. Finally, analysts at Bank of America raised their price target on shares of IDEXX Laboratories from $93.00 to $94.00 in a research note to investors on Friday, April 20th. They now have a “buy” rating on the stock.

Shares of IDEXX Laboratories (IDXX) traded down 0.69% during mid-day trading on Monday, hitting $92.59. IDEXX Laboratories (IDXX) has a one year low of $63.83 and a one year high of $95.95. The company has a market cap of $5.096 billion and a P/E ratio of 32.35.

IDEXX Laboratories, Inc. (IDEXX) develops, manufactures and distributes products, and provides services primarily for the veterinary and the production animal, water testing and dairy markets.

Stay ahead of the market with Analyst Ratings Network's daily email update that provides a summary of analysts' upgrades, downgrades and new coverage. Click here to register now.

Posted by Web Inquirer Staff on 26 Jun 2012. Filed under Markets. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.